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Abstract
We have successfully established and characterized a genetically modified pig line with
ubiquitous expression of LEA29Y, a human CTLA4-Ig derivate. LEA29Y binds human B7.1/
CD80 and B7.2/CD86 with high affinity and is thus a potent inhibitor of T cell co-stimulation
via this pathway. We have characterized the expression pattern and the biological function
of the transgene as well as its impact on the porcine immune system and have evaluated
the potential of these transgenic pigs to propagate via assisted breeding methods. The anal-
ysis of LEA29Y expression in serum and multiple organs of CAG-LEA transgenic pigs
revealed that these animals produce a biologically active transgenic product at a consider-
able level. They present with an immune system affected by transgene expression, but can
be maintained until sexual maturity and propagated by assisted reproduction techniques.
Based on previous experience with pancreatic islets expressing LEA29Y, tissues from
CAG-LEA29Y transgenic pigs should be protected against rejection by human T cells. Fur-
thermore, their immune-compromised phenotype makes CAG-LEA29Y transgenic pigs an
interesting large animal model for testing human cell therapies and will provide an important
tool for further clarifying the LEA29Y mode of action.
Introduction
Xenotransplantation, the use of living cells, tissues or organs of animal origin for the treatment
of human patients, is a promising approach for overcoming donor organ shortages. While the
transplantation of xenogeneic cornea grafts or pancreas islets is already at an advanced pre-
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clinical stage or has entered clinical trials [1, 2], the use of complex tissue or even complete,
vascularized organs is hampered by more diverse graft rejection mechanisms. Nonetheless,
xenotransplantation provides the opportunity to address these problems by the genetic modifi-
cation of the donor animals. One of the fundamental advantages of xenotransplantation is the
transgenic expression of immune-modulatory agents in xenografts prevents their rejection at
the transplantation site while the systemic immunosuppressive load on the recipient is, at the
same time, reduced to a tolerable level.
The genetic modification of donor pigs for xenotransplantation has so far primarily
addressed complement-mediated rejection processes and coagulation incompatibilities ([3],
reviewed in [4]). Some studies have also attempted to overcome cellular rejection of porcine
xenografts. The cells from transgenic pigs expressing HLA-E/beta2-microglobulin have been
shown to be protected against lysis by human natural killer cells [5]. The main focus, however,
has been on preventing the activation of human T cells by blocking the co-stimulatory signal
between CD28 and B7.1/CD80 or B7.2/CD86 via expression of CTLA4-Ig (Abatacept1) or its
more effective derivative LEA29Y (Belatacept1). Restricting the expression of LEA29Y exclu-
sively to the pancreatic beta cells [6] as well as expressing human CTLA4-Ig solely in neurons
[7] or in KRT14-producing cells [8] has generated promising data. In different transplantation
experiments, the local transgene expression proved sufficient to protect the transplant site
from T cell infiltration while the transgenic pigs remained healthy and could be propagated by
normal breeding. To more effectively manage donor pigs in xenotransplantation, however, the
use of several tissues from a single donor is desirable. In addition, in the case of more complex
grafts such as solid organs, expressing an immune modulator in the entire tissue might be supe-
rior to its production in a single-cell type only. Thus, the ubiquitous CTLA4-Ig or LEA29Y
expression across a range of porcine tissues or organs potentially attractive for transplantation
would be preferable. Such a ubiquitous abundance of T cell blocking agents might, however,
result in a chronic impairment of the immune system in the donor organism, which would
then affect the reproducibility of these animals, and therefore, the availability of donor organs.
Recently, two studies evaluated the effect of ubiquitous expression of co-stimulatory blockers
in pigs. A transgenic pig with an inducible expression of porcine CTLA4-Ig did not show an
affected immune system, but the suitability of such organs in transplantation experiments
remains elusive [9]. On the other hand, pigs that constitutively produce porcine CTLA4-Ig
[10] were severely immunocompromised and could not be maintained for propagation.
Here, we report the production of transgenic pigs that ubiquitously express LEA29Y. We
characterize the expression pattern and biological function of the transgene as well as its impact
on the porcine immune system and evaluate the potential for these transgenic pigs to be propa-
gated by assisted breeding methods.
Materials and Methods
Bioinformatic evaluation
The species-specificity of the binding regions of the CTLA4 extracellular domain and its recep-
tors B7.1/CD80 and B7.2/CD86 was examined by multi-species comparison, using the respective
sequences from human, macaque, marmoset, mouse, rat, cat, dog, horse, cattle, sheep, pig, and
river dolphin as well as chicken that were sourced from the GenBank database (http://blast.ncbi.
nlm.nih.gov). The alignment was performed by use of the ClustalW algorithm of the BioEdit
bioinformatics package [11] and adapted manually. The binding domains of the proteins as well
as the positions contributing to protein-protein interaction were defined as previously described
[12], and the codons under putative positive selection were identified using the codonML pro-
gram from the PAML software package (http://abacus.gene.ucl.ac.uk/software/paml.html). The
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amino acid consensus sequences as well as the conservation of the respective positions were cal-
culated by the JalView package (www.jalview.org), while the PHYLIP package (http://evolution.
genetics.washington.edu/phylip.html) was used to generate phylogenetic trees according to [13].
Vector design and construction
For ubiquitous expression of the synthetic LEA29Y gene, we made use of the regulatory prop-
erties of the previously described CAG-Cre plasmid [14], excising the Cre gene via the adjacent
EcoRI and NotI sites and then replacing it by a synthetic multiple cloning site (MCS) that was
generated by aligning the oligos EH53 and EH35 (all oligonucleotides (S1 Table) were pur-
chased from Thermo Fisher Scientific, Waltham, MA, USA) to produce a CAG-MCS-pA ele-
ment. In parallel, we deleted an XbaI site in a neomycin selection cassette (neo) [15] by cutting,
T4-polymerase (Thermo Fisher Scientific, Waltham, MA, USA) induced fill-in, and religation.
To combine the CAG-MCS-pA element and the selection cassette, we replaced the original
MCS in the pBSK(+) vector (Agilent, Santa Clara, CA, USA) with a synthetic element that was
generated by aligning the oligos NK53 and NK35 via the NotI and KpnI sites. First, we cloned
the selection cassette that had been excised by NsiI and BamHI into the PstI/BglII linearized
plasmid; second, we introduced the SpeI/PstI-excised CAG-MCS-pA fragment into the XbaI/
NsiI-linearized plasmid. Eventually, aHindIII/PstI-excised LEA29Y element [6] was intro-
duced into the vector using theHindIII/PstI sites in the MCS. After sequencing, the plasmid
was prepared endotoxin-free, and the CAG-LEA/neo element was excised from the backbone
by AscI according to [9].
Transgenic animals
The founder pigs were generated by somatic cell nuclear transfer (SCNT) and embryo transfer
(ET) using primary fetal fibroblasts (PFFs) from a wild-type (WT) German Landrace boar
[16]. Pregnancies were routinely monitored by ultrasound examination. Birth was induced on
gestation day 114 by intramuscular administration of 0.175 mg Cloprostenol (Estrumate1,
Intervet GmbH, Unterschleissheim, Germany). The founder pigs were kept with the foster
mother for 5 weeks before weaning under a conventional agricultural environment and then
euthanized at that age to sample tissue for characterization and preservation of primary kidney
cells (PKC) and ear fibroblasts (PEF). Similarly, the offspring produced by re-cloning the stron-
gest expressing founder boar were born and kept with the sow, but for one re-cloned litter, a
preventive daily antibiotic treatment was started at weaning by the oral administration of 25
mg/kg/day amoxicillin clavulanic acid (Synulox1 500, Zoetis GmbH, Berlin, Germany). The
animals were submitted to additional antibiotic treatment in the case of acute infections. The
presence of the transgene was detected by conventional end-point PCR using the transgene
specific primers LEAf and NEOr as well as the primers ACTf-ACTr for the ACTB gene as a
control. PCR included an initial denaturation of 5 min at 95°, 35 cycles of 30 sec at 95°C, 30 sec
at 56°C, 45 sec at 72°C and final steps of 10 min at 72°C and 15 min at 4°C. To determine of
transgene copy numbers and numbers of integration sites, Southern blotting was conducted on
the founder and F1 generation animals. For this technique, genomic DNA was fragmented
using the XbaI restriction site, transferred to a Hybond-N+ Nylon Membrane (GE Healthcare,
Munich, Germany) in a semi-dry manner and detected by radio-labelled (α32P-dCTP; Perkin-
Elmer, Groningen, Netherlands) probes specific for the neomycin resistance cassette. At regu-
lar time points, blood was drawn from the jugular vein of the animals for isolation of peripheral
blood mononuclear cells (PBMCs). According to animal welfare guidelines, pigs were sacrificed
in the case of untreatable, severe illness, and samples of their tissues were preserved for further
characterization. Both the generation of transgenic animals as well as interventions on re-
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cloned animals were performed with permission of the local regulatory authority, Regierung
von Oberbayern (ROB), Sachgebiet 54, 80534 München (approval numbers: AZ 55.2-1-54-
2532-70-12 and AZ 55.2-1-54-2532-163-14). Applications were reviewed by the ethics com-
mittee according to §15 TSchG German Animal Welfare Law. The animals were euthanized
under Ketamine (Ursotamin1, Serumwerk Bernburg, Germany) and Azaperone (Stresnil1,
Elanco Animal Health, Bad Homburg, Germany) anesthesia by intravenous injection of T611
(Intervet GmbH), according to the manufacturer’s instructions.
Tissue preparation
After euthanasia of the founder boars and age-matched WT controls, samples from the heart,
kidney, liver, lung, muscle, pancreas, spleen, intestine and blood serum were frozen in liquid
nitrogen or fixed in para-formaldehyde and embedded in paraffin. From re-cloned founder
and F1 generation animals, the same tissue, excluding intestine but additionally including adre-
nal gland, thyroid gland, lymph node and skin tissues, were sampled. The samples of F1 gener-
ation animals were fixed in 4% buffered formalin and Methacarn (Methanol-Carnoy) and
embedded in paraffin.
ELISA
Frozen tissue was crushed and lysed in a buffer consisting of 125 mMMannitol, 40 mM Sac-
charose, 5 mM EDTA and 5 mM Pipes/Tris. Proteinase inhibitor (Halt™, Thermo Fisher Sci-
entific, Waltham, MA, USA) was added according to the manufacturer’s recommendations.
The protein concentration was measured by Rotiquant1 (Carl Roth, Karlsruhe, Germany),
according to the manufacturer´s protocol. LEA29Y protein abundance in the respective tis-
sues was determined by ELISA, using a polyclonal rabbit anti-human IgG antibody (Dako,
Jena, Germany; dilution 1:570) for coating and a polyclonal HRP-conjugated rabbit anti-
human-IgG antibody (Dako, Jena, Germany; dilution 1:4800) for detection. Human serum
from a healthy volunteer was diluted 1:30,000 and 1:300,000 in a washing buffer and used as a
positive control.
Immunohistochemistry
To detect LEA29Y expression, staining in the fixed tissue of F1 generation transgenic animals
and WT siblings was performed using mouse-anti-human IgG Fc antibody (Jackson Immuno
Research, Westgrove, PA, USA), biotinylated SP-conjugated goat-anti-mouse IgG antibody
(Jackson Immuno Research, Westgrove, PA, USA) and VECTASTAIN Elite ABC-Peroxidase
Kit (#PK-6100, Vector Laboratories, Burlingame, CA, USA). Immunoreactivity was visualized
using 3,3-diaminobenzidine tetrahydrochloride dihydrate (DAB) (brown color), while nuclear
counterstaining was performed with hemalum (blue color).
Biological function
The binding capacity of LEA29Y was evaluated by incubating serum from transgenic animals
and WT controls with the CD80/CD86-expressing porcine B-cell line L23 [17] in serial dilu-
tions of serum from wild-type and CTLA4-Ig transgenic pigs. The IgG tail of LEA29Y was
detected by FACS analysis using a goat anti-human IgG-FITC antibody according to [18]. The
CD80/CD86-positive human B-cell line Laz509 was generated from Epstein-Barr virus-trans-
formed B cells as in [19]. The potential of LEA29Y containing pig serum to inhibit proliferation
of human T cells was investigated by mixed-lymphocyte reaction using PBMC from human
volunteer donors in the presence of the porcine antigen-presenting cell line L23 according to
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[9]. In total, 1 x 105 human peripheral blood mononuclear cells (hPBMCs) were stimulated
with 2 x 103 irradiated (30 Gy) L23 cells, Laz509 cells or allogeneic PBMCs. Cultivation was
performed in the presence of sera obtained from wild-type and LEA29Y transgenic pigs. Prolif-
eration was determined after 5 d by [3H]-TdR incorporation.
Clinical phenotype
CAG-LEA pigs were examined daily for visible signs of infection and treated with additional
antibiotics when necessary. Porcine PBMCs were isolated fromWT and transgenic animals by
density gradient centrifugation, as described elsewhere [18], and then cryopreserved. The
thawed cells were washed with PBS (PAN-Biotech) with 10% porcine plasma (in-house prepa-
ration) and transferred to 96-well plates for flow cytometry staining. The following primary
monoclonal antibodies (mAbs) were used in various combinations: CD3-PE-Cy7 (clone BB23-
8E6-8C8, BD Biosciences, Franklin Lakes, NJ, USA), CD4-PerCP-Cy5.5 (clone 74-12-4, BD
Biosciences, Franklin Lakes, NJ, USA), CD8α-FITC (clone 11/295/33, in-house preparation),
CD8α-PE (clone 76-2-11, BD Biosciences, Franklin Lakes, NJ, USA), CD27-AlexaFluor647
(clone b30c7, in-house preparation), CD45RC-biotinylated (clone 3a56, in-house preparation)
and TCR-γδ-biotinylated (clone PPT16, in-house preparation) mAbs. The biotinylated pri-
mary antibodies were labeled with Streptavidin-Brilliant Violet 421 (BioLegend, San Diego,
CA, USA) in a second incubation step. To identify B cells and regulatory T cells, samples were
fixed and permeabilized using a Foxp3 staining buffer kit (eBioscience, San Diego, CA, USA)
and incubated with anti-CD79α-PE (clone HM57, Dako, Jena, Germany) or anti-Foxp3-PE
(clone FJK-16s, eBioscience, San Diego, CA, USA) mAbs, respectively. To investigate produc-
tion of IFN-γ and TNF-α, defrosted PBMCs were incubated for four hours in RPMI1640 with
stable glutamine supplemented with 10% fetal calf serum, 100IU/ml penicillin, 0.1 mg/ml
streptomycin (all from PAN-Biotech, Aidenbach, Germany), 50 ng/ml phorbol-myristate-
acetate (PMA, Sigma-Aldrich, St. Louis, MO, USA), 500 ng/ml ionomycin (Sigma-Aldrich,
St. Louis, MO, USA) and 1 μg/ml Brefeldin A (BD Biosciences, Franklin Lakes, NJ, USA) at
37°C and 5% CO2 in 96-well plates with 5 x 10
5 PBMCs/well. The cells were harvested and sub-
jected to flow cytometry staining with mAbs against CD4 (see above), followed by fixation and
permeabilization with BD Cytofix/Cytoperm (BD Biosciences, Franklin Lakes, NJ, USA) and
incubation with anti-TNF-α-BrilliantViolet605 (clone MAb11, BioLegend, San Diego, CA,
USA) and anti-IFN-γ-PE (clone P2G10, BD Biosciences, Franklin Lakes, NJ, USA) mAbs. For
samples that had undergone fixation and permeabilization, the LIVE/DEAD Near-IR Dead
Cell Stain Kit (Life Technologies) was used to exclude dead cells from analysis, according to
standard procedures. All samples were analyzed with a FACSCanto II flow cytometer (BD Bio-
sciences, Franklin Lakes, NJ, USA) equipped with FACSDiva software, version 6.1.3 (BD Bio-
sciences, Franklin Lakes, NJ, USA).
Histological analysis of transgenic lymph nodes
The lymph nodes of a re-cloned six-month-old transgenic animal were examined histologically
as an example of secondary lymphatic tissue to identify the morphological developmental stage
of this organ. The lymph nodes of WT pigs (fattening hybrids; age 19 days, 37 days, 4 months,
6 months and 8 months; Ln. jejunalis, Ln. popliteus, Lnn. aortici thoracici, Ln. cervicalis super-
ficialis dorsalis) served as control samples. The Ln. tracheobronchialis medius of the transgenic
pig was initially cryoconserved and fixed afterward by first immersing the deep frozen, pre-
pared tissue in cold (4°C) buffered formalin and then incubating for 72 h at room temperature.
Afterward, the samples were embedded in paraffin. Lymph nodes from the archive of the Insti-
tute of Anatomy, Histology and Embryology of the University of Veterinary Medicine Vienna
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were used as controls. All samples were cut into 3 μm thick sections and mounted on silanized
SuperFrost1Plus slides (Menzel-Gläser, Braunschweig, Germany). After deparaffinization, the
sections were rehydrated and transferred into PBS (phosphate buffered saline, pH 7.4). Endog-
enous peroxidase activity was blocked with 0.6% (v/v) H2O2 in distilled water. The sections
were pre-treated by microwaving them in 0.01 M citrate buffer (pH 6.0). Non-specific binding
activity was blocked with normal goat serum (Dako, Jena, Germany; 150 μl/10 ml PBS) at
room temperature. T cell-specific staining was performed with a monoclonal mouse anti-por-
cine CD3 antibody (clone PPT3; dilution 1:75; Institute of Immunology, University of Veteri-
nary Medicine, Vienna, Austria). To detect proliferating cells, corresponding sections were
incubated with a monoclonal mouse anti-Ki67 antibody (clone 7B11, dilution 1:100; Invitro-
gen, Life Technologies Austria, Vienna, Austria). The incubation with primary antibodies
lasted overnight at 4°C. Antibody binding was detected by the BrightVision poly HRP-Anti-
Mouse IgG kit (ImmunoLogic, Duiven, The Netherlands), according to the manufacturer’s
protocol. The reactions were visualized with diaminobenzidine (Sigma-Aldrich, Vienna, Aus-
tria) in 0.03% H2O2 in Tris-buffered saline (pH 7.4). All sections were counterstained with
hematoxylin, dehydrated and mounted using a medium soluble in xylene. For a negative con-
trol, normal goat serum was used instead of primary antibodies (data not shown). All sections
were examined using a light microscope.
Reproduction
In vitro fertilization (IVF) was performed using in vitromatured (IVM) oocytes [16] and fro-
zen sperm collected from the epididymides of a re-cloned CAG-LEA boar [20]. For insemina-
tion, approximately 20–25 oocytes with expanded cumulus cells were incubated with
spermatozoa (1.0–5.0 x 106 cells/ml) in porcine fertilization medium (Research Institute for the
Functional Peptides, Yamagata, Japan) for 7 h [21]. After insemination, cumulus cells and
excess sperm were removed from the eggs, and only eggs with one or two visible polar bodies
were used for the experiments. The eggs were assessed based on the ratio of normal fertilization
(eggs with two pronuclei) and blastocyst formation at day 7. ET was performed using only
selected eggs in which one or two polar bodies were observed. Pregnancy was routinely moni-
tored by ultrasound examination. Birth was induced on day 114 by intramuscular administra-
tion of 0.175 mg Cloprostenol (Estrumate1, Intervet GmbH). The piglets were kept with their
foster mother for 5 weeks before weaning and were housed under a conventional agricultural
environment.
Results
Co-stimulation proteins are distinctly conserved among mammals
The bioinformatic evaluation of the binding sites of mammalian CTLA4 and its receptors
B7.1/CD80 and B7.2/CD86 was performed to predict the effect of LEA29Y on the porcine T
cell regulation. We found that the binding domain of CTLA4 is strongly conserved among the
examined species, whereas the homology in B7.1/CD80 and B7.2/CD86 is lower (Fig 1). This is
supported by the identification of positively selected sites, where B7.2/CD86 and particularly
B7.1/CD80 showed a tendency toward evolutionary adaption in mammals, whereas this ten-
dency was revealed only for two positions in CTLA4. Interestingly, the difference between
human and porcine sequences is higher than expected (Fig 2), and these differences even affect
positions that have been described to be essential for co-stimulatory interaction [12]. This is
particularly remarkable in the C-terminal parts of the B7.1/CD80 and B7.2/CD86 binding
domains, where the human DAFKR motif corresponds to a porcine GSYKL while the human
TGMIR peptide corresponds to the porcine HGLVP, respectively. These differences are not
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specific to a human or pig, but rather, represent common properties of the primate and ungu-
late branches in the evolutionary tree. The diversity of CTLA4 is less obvious, but we found
that the well-defined MYPPPY peptide is conserved among all examined species with the
exception of the pig, where an L replaces the M in this motif. The influence of the A29Y and
L104E modifications that discriminate LEA29Y from CTLA4-Ig is hard to estimate, as the
effect of these substitutions is without doubt [22]; however, there is no considerable informa-
tion on how these modifications influence the binding properties of CTLA4 on a molecular
level. It is of note, however, that while A29 is conserved among most species, L at position
104 is unique to human, and the position is also diverse among the other species examined,
with a W present in the majority of species, including the pig. Taken together, these findings
suggest that the effect of LEA29Y on the porcine immune system should be different from the
described expression of porcine CTLA4-Ig [10].
Fig 1. Binding regions in mammalian CTLA4, CD80 and CD86. The species are arranged according to their phylogenetic pattern, with positions
highlighted in light gray that were identified as essential for binding (according to [12]) and positions that differ between human and pig highlighted in
dark gray. The phylogenetic trees represent genetic distance trees, with relationships also occurring in most parsimony trees shown as bold lines and
bootstrap values indicating when branches occurred >70 times in the consensus of 100 genetic distance trees. For each alignment, the consensus
amino acid sequence is shown below and the degree of conservation shown above the alignment. Sites of positive selection were defined by the
codonML software, using the model algorithms 3 (discrete, naïve empirical bayes) and 8 (beta&omega>1, naïve empirical bayes). The sites under
positive selection are marked with an asterisk, and those proposed to be under significantly (p>95%) positive selection are marked with two asterisks.
The two positions that have been modified in human CTLA4 to generate LEA29Y are marked by an arrow.
doi:10.1371/journal.pone.0155676.g001
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CAG promoter drives ubiquitous expression of LEA29Y in transgenic
pigs
For strong and ubiquitous expression of LEA29Y, we made use of a CAG-plasmid [14], com-
prising a CMV enhancer element, the chicken ACTB core promoter and genomic fragments
from the rabbit HBB gene that provide splicing and polyadenylation of the transgene (Fig 3A).
After transfection of the vector into PFFs and their positive selection, we used a mixed popula-
tion of genetically modified cell clones in a single SCNT experiment and transferred 127 recon-
structed embryos to an estrus-synchronized gilt that delivered three transgenic piglets to term.
The offspring thrived until weaning at 5 weeks of age with no obvious signs of infection, at
which point they were sacrificed for the characterization of transgene expression.
LEA29Y protein abundance in tissues and serum was detected by an ELISA assay specific
for the human IgG tail of the synthetic LEA29Y protein, which indicated that the three founder
animals each represent distinct transgenic lines, differing presumably by the integration site(s)
of the transgenes (Fig 3B). Although the absolute amount of detected protein differed consider-
ably between the examined tissues, for any given tissue, the ratio to each other among the
founder animals remained similar. The localization of LEA29Y expression across a range of
Fig 2. Genetic distance betweenmammalian CTLA4, B7.1/CD80 and B7.2/CD86. The percentage of amino acid identities between pairwise
comparisons are shown as a matrix for CTLA4 (A), CD80 (B) and CD86 (C). The distribution of pairwise identities was calculated in segments of 4% (D)
and illustrates higher amino acid conservation in CTLA4 compared to CD80 and CD86.
doi:10.1371/journal.pone.0155676.g002
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potentially transplantation-relevant organs and tissue was evaluated by immunohistochemistry
using an antibody specific for the human IgG tail of the transgene. A positive staining for
LEA29Y was obtained in all transgenic samples that were analyzed (Fig 4A), while staining
remained absent for WT controls (Fig 4B). LEA29Y could be constantly detected in endothelial
cells including capillaries as well as in the interstitium. Furthermore, several organ- and tissue-
specific cell types, such as pulmonary alveolar cells, exocrine pancreas cells, bile duct cells of
the liver, and the stratum spinosum cell layer of the skin, stained immuno-positive. In endo-
crine organs, expression of the transgene could be detected in endocrine cells of the Langerhans
islet, the thyroid gland, and the cortex and medulla of the adrenal gland (adrenal gland not
shown). Additionally, intravascular serum stained positive for LEA29Y.
Transgenic LEA29Y binds to antigen-presenting cells and prevents T
cell activation in vitro
To evaluate the potential of recombinant LEA29Y to bind its receptors, we incubated the por-
cine CD80/CD86-positive B cell line L23 with serum from the founder animals or, alterna-
tively, with serum from wild-type controls (Fig 5A). The concentration-dependent signal in
serial dilution studies indicated an abundance of biologically active LEA29Y in the serum of
the founder animals and confirmed high levels of LEA29Y in the serum of pig #9908 and lower
as well as detectable levels of the transgene in #9910 and #9909. The decrease of the binding
signal in #9908 at very high serum concentrations was explained by the classical “hook” or pro-
zone effect. In a more specific assay, we addressed the extent to which recombinant LEA29Y
blocks the interaction between porcine CD80/CD86 and human CD28, thereby down-regulat-
ing human anti-pig T cell activation. When in vitro stimulation of human PBMCs with porcine
L23 cells was performed in the presence of sera from LEA29Y transgenic pigs, proliferation
Fig 3. Establishment of CAG-LEA pigs. (A) The CAG promoter, containing a CMV enhancer element, the chicken beta-actin core
promoter as well as a genomic element from the rabbit HBB gene, were used to drive ubiquitous expression of LEA29Y. A neomycin
resistance cassette (neo) was used to achieve positive selection. Arrows indicate the position of primers used for genotyping the animals.
The XbaI restriction site used for digesting genomic DNA for Southern Blot analysis is indicated as well as the neo-specific probe used for
hybridization. (B) LEA29Y protein abundance was measured in mg/ml by an ELISA assay specific for the human IgG tail of LEA29Y in
different tissues of three founder animals and aWT control.
doi:10.1371/journal.pone.0155676.g003
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was significantly reduced in these sera compared to sera from wild-type control animals. Thus,
recombinant LEA29Y not only binds to porcine CD80/CD86 but also prevents the binding of
this molecule to its receptor CD28 (Fig 5B).
Interestingly, the inhibitory effect of the respective founder lines reflected the findings from
the expression and binding studies, but the difference in the proliferation assay was not very
pronounced.
LEA29Y pigs do not develop a mature immune system
To evaluate the maximum effect of ubiquitous LEA29Y expression on the porcine immune sys-
tem, we reproduced #9908, the most potent founder pig, by cloning. We obtained 2 litters com-
prising 5 and 8 offspring, respectively, which were maintained in the same way as the founder
Fig 4. Localization of LEA29Y expression in F1 generation. Immunohistochemistry was performed using an antibody specific for the human
IgG tail of LEA29Y. (A) LEA29Y was predominantly detected in endothelial cells including capillaries and interstitia, as well as in organ- and
tissue-specific cell types such as pulmonary alveolar cells, exocrine pancreas cells, bile duct cells of the liver, or the stratum spinosum cell layer
of the skin. Endocrine cells of the Langerhans islet (indicated by an arrow) as well as the thyroid gland exhibited strong staining. Additionally,
intravascular serum stained positive for LEA29Y. (B) No immune staining could be detected in WT control tissue. Chromogen: DAB; nuclear
staining: hemalum; scale bar = 200 μm. Inset in pancreas: Giemsa stain of the corresponding pancreas region to demonstrate Langerhans islet.
Lymph node: L. tracheobronchialis medialis.
doi:10.1371/journal.pone.0155676.g004
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animals. Again, the animals were clinically unaffected until weaning but started showing signs of
acute and chronic infection shortly afterward, with different progression exhibited in different
animals. Most of the animals had to be sacrificed by the age of 3 months, but with intermittent
treatment, two animals were raised up to an age of 10 months. Of those animals, we isolated
PBMCs at an age of 6 months and characterized various lymphocyte subpopulations (Fig 6).
Contrary to the hypothesis that LEA29Y primarily acts on T cell activation, the frequency of B
cells was significantly reduced in the blood of transgenic animals compared to age-matchedWT
animals, whereas consequently, the proportion of T cells increased (Fig 6A). The analysis of
major T cell subpopulations did not indicate a difference in the frequency of total γδ or αβ T cells
(Fig 6B), nor in that of cytotoxic T cells and T-helper cells (Fig 6C). Only the frequency of Tregs
showed a significant reduction in the transgenic animals (Fig 6D). However, when CD4+ T cells
were examined in more detail, we observed a very low frequency of CD4+CD8α+ T cells in
CAG-LEA animals compared to age-matchedWT pigs. Instead, the frequency of CD4+CD8α+ T
cells was similar to that found in 3-week old piglets (Fig 7A) [23]. Previous work had shown that
CD8α expression on porcine CD4+ T cells is a consequence of activation and memory formation
[24]; thus, these findings indicate that activation and memory formation of CD4+ T cells is
Fig 5. Biological evaluation of transgenic founder animals. (A) Binding studies of LEA29Y to the CD80/
CD86-positive porcine B cell line L23. Cells were incubated with serial dilutions of sera from the three founder
animals as well as from wild-type controls. Binding of LEA29Y was assessed by using a goat anti-human
IgG-FITC antibody. Labeled cells were analyzed by flow cytometry. The results are expressed as the mean
fluorescence intensity. (B) Inhibition of human anti-pig T cell proliferation by serum from LEA29Y-tg pigs. 105
human PBMC were stimulated with 2 x 103 irradiated L23 cells. Cultivation was performed in the presence of
sera taken from transgenic and wild-type control pigs. Proliferation was determined after 5 d by [3H]-TdR
incorporation (ccpm, counts/min). The results are expressed as the mean ± SD of triplicate cultures.
doi:10.1371/journal.pone.0155676.g005
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severely impaired in CAG-LEA pigs. In addition, although the frequency of CD8α+ CD27- and
CD8α+ CD45RC- CD4+ T cells was strongly reduced in the transgenic pigs compared to age-
matched controls, it again resembled the frequency present in 3-week-oldWT piglets (Fig 7B
and 7C). Porcine CD8α+CD27- CD4+ T cells have been shown to resemble effector memory T
cells [25], whereas CD45RC- CD4+ T cells also represent memory cells [24]. The phenotype of
CD4+ T cells in CAG-LEA pigs thus resembles juvenile pigs rather than age-matchedWT
Fig 6. Immunological profile of re-cloned #9908 pigs. PBMCs isolated from animals re-cloned from #9908 primary cells (LEA, n = 2)
were analyzed by flow cytometry for the frequency of major lymphocyte subpopulations and compared to PBMCs isolated from age-
matched wild-type pigs (WT, n = 11). (A) Frequencies of NK cells (CD3-CD8α+), B cells (CD79α+) and T cells (CD3+) as a percent of
lymphocytes. (B) Frequencies of γδ (CD3+TCR-γδ+) and αβ T cells (CD3+TCR-γδ-) as a percent of total T cells. (C). Frequencies of cytolytic
T cells (CTL; CD3+TCR-γδ-CD4-CD8αhigh), T-helper cells (Th; CD3+TCR-γδ-CD4+Foxp3-) and regulatory T cells (Treg; CD3+TCR-
γδ-CD4+Foxp3+) as a percent of αβ T cells. (D) Frequencies of regulatory T cells (Treg) as a percent of αβ T cells with a different scaling of
the y-axis. Asterisks indicate significant differences betweenWT and LEA lymphocyte subpopulations (p < 0.05).
doi:10.1371/journal.pone.0155676.g006
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controls [23]. This interpretation was further supported by a strongly reduced frequency of
CD4+ T cells with the capacity to produce IFN-γ, TNF-α or both cytokines together following
PMA/ionomycin stimulation (Fig 7D). As already shown in Fig 6D, 6-month-old CAG-LEA
pigs had strongly reduced frequencies of CD4+FOXP3+ Tregs, and these frequencies were even
lower than those found in three-week-old WT piglets (Fig 7E).
At an age of 6 months, a histological analysis of CAG-LEA transgenic pig lymph nodes as
an example of secondary lymphatic tissue revealed retarded morphological development com-
pared to WT animals (Fig 8). Testing consistently revealed no difference between the samples
regarding T cell localization and the amount of proliferating T cells. The follicles were nearly
free of T cells in all samples. Regarding the development of follicles, the lymph nodes of the
transgenic pigs resembled those at the developmental stage of 19- to 37-day-old WT animals
rather than those of age-matched controls. The follicles of transgenic lymph nodes were only
approximately half the size of WT follicles at the same age. As in young WT animals, they
formed near the trabecules, but the signs of further differentiation, such as reaction centers
with heavily proliferating centroblastic and mildly proliferating centrocytic dark and pale
zones, respectively, were completely lacking.
Fig 7. T cell subpopulations in transgenic pigs. PBMCs were isolated from LEA pigs, 3-week-old wild-type (WT) piglets and 6-month old WT pigs and
analyzed by flow cytometry for the phenotype of CD4+ T cells and production of IFN-γ and TNF-α. (A) CD4 and CD8α expression on lymphocytes. Total
CD4+ T cells were gated (black gates, red population) and analyzed for CD8α expression (green gates). The numbers indicate percent CD8α+ cells
within CD4+ T cells. (B) CD8α and CD27 expression on gated CD4+ T cells. (C) CD8α and CD45RC expression on gated CD4+ T cells. (D) IFN-γ and
TNF-α production in gated CD4+ T cells following stimulation with PMA/Ionomycin for four hours as a representative flow cytometry plot (upper panel)
and a graph comprising data of all animals as the mean value + standard deviation (lower panel). (E) CD4 and Foxp3 expression of lymphocytes. The
numbers indicate the percent of gated CD4+Foxp3+ regulatory T cells within lymphocytes. The data are representative of two three-week-old WT pigs,
two tg pigs and two six-month-old pigs.
doi:10.1371/journal.pone.0155676.g007
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CAG-LEA transgenic pigs reproduce by in vitro fertilization
The compromised immune system of the first 2 litters of re-cloned CAG-LEA pigs required
euthanasia at a maximum age of 10 months without any of them reaching the age of fertility.
Interestingly, we did not find evidence for sperm production in the epididymides of even the
oldest animals. To improve vitality, growth and development, we started prophylactic antibiotic
Fig 8. Lymph node histology in transgenic pigs. Developmental stage of lymph nodes of a 6-month-old CAG-LEA transgenic pig (B, E) in
comparison with WT porcine lymph nodes; the age of the animals was 19 days (A, D) and 6 months (C, F). Immunohistochemistry using the
PPT3 anti-CD3 antibody demonstrates nearly T cell-free follicles (Fo) near the trabecules (T) in all samples. Follicles in samples of 6-month-
old WT animals were generally larger than in transgenic or young animals (compare C versus A and B). Follicles of 6-month-old WT porcine
lymph nodes showed a distinct reaction center (F) with heavily proliferating centroblasts in the dark zone (DZ) and less proliferating cells in
the pale zone (PZ)–comparing strong and weak Ki67 immunopositivity (proliferation marker) in DZ and PZ, respectively. In contrast, marked
proliferation of lymphocytes could be detected in either the follicles of transgenic (E) nor 19-day-old WT animals (D). The amount of
proliferating T cells did not seem to differ between the samples. Visualization of the immunoreaction diaminobenzidine—horseradish
peroxidase (positive staining = brown), counterstaining hematoxylin, scale bar = 200 μm.
doi:10.1371/journal.pone.0155676.g008
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treatment around weaning and maintained daily application within a third litter of three re-
cloned animals throughout their lifespan. Although this failed to prevent regular infections, it
supported sexual maturation in one animal that was raised up to an age of 10 months. Isolated
freeze-thawed sperm from the epididymides of this animal showed sufficient viability and motil-
ity for IVF. Thirty-percent of oocytes were successfully penetrated (15/50), and the majority
showed normal fertilization (86.7%, 13/15). The resulting blastocyst rate as well as the number
of cells per blastocyst was within the range reported in previous IVF studies [26, 27] (S1 Fig).
This promising finding encouraged us to transfer 515 IVF-generated embryos to 2 foster
sows, which delivered a total of 20 offspring. The Mendelian rules of inheritance predicted
approximately 50% transgenic offspring, a benchmark that, with 8 out of 20, was almost met in
these litters (S2A Fig). To exclude the possibility of segregating integration sites of the trans-
gene, we performed Southern Blot analysis on the founder animals as well as on the F1 genera-
tion piglets. This analysis showed identical integration patterns for the founder boar and its F1
generation offspring, suggesting one single CAG-LEA integration site (S2B Fig). In both litters,
transgenic as well as WT siblings were viable and remained clinically indistinguishable from
each other until weaning. From that time point onward, transgenic piglets started to suffer
from regular bouts of infections and stayed behind their WT litter mates in terms of growth
and bodily development. The F1 generation animals were individually treated with antibiotics
upon clinical indication due to infectious episodes. None of the animals were treated preven-
tively. Three of the genetically modified F1 animals underwent a full pathological-anatomical
examination at the Institute for Veterinary Pathology at LMUMunich. In these instances, no
indication of affected organ development was detected. However, the severity of clinical epi-
sodes in these CAG-LEA pigs was markedly reduced compared to their counterparts that had
been generated by the re-cloning of the original founder. This is consistent with an impaired T
cell repertoire in transgenic F1 animals that was evaluated by analysis of PBMCs isolated in
3–4 week intervals between the ages of 10 weeks and 6 months.
Similar to the re-cloned founder animals and in contrast to WT animals, the CD4+ T cell
population in the transgenic offspring mainly comprised naïve (CD8α-CD27+) T cells, whereas
the proportion of effector memory (CD8α+CD27) T cells was reduced (S2C Fig).
The presence of LEA29Y in sera from genetically modified F1 offspring and WT control lit-
termates was assessed by analyzing the binding to porcine L23 as well as human Laz509 cells
(both express the LEA29Y target CD80/86). Neither in L23 nor Laz509 cells did we observe
any dose-response reactivity of sera fromWT animals (Fig 9A). However, the baseline fluores-
cence intensity found with sera fromWT animals was higher in Laz509 cells than in L23 cells.
This results from the fact that the FITC-labelled goat anti-human Ig antibody, which was used
to detect LEA29Y, binds to surface immunoglobulin on the human Laz509 B cell line but not
to that on porcine L23 cells. Consistent with data obtained with serum from the founder animal
#9908 (Fig 5A), the sera from all LEA29Y transgenic F1 pigs produced a linear dose-response
signal at lower concentrations in L23 and Laz509 cells and the above described hook, or pro-
zone, effect for higher concentrations. The findings from the #9908 founder animal were simi-
larly confirmed in proliferation assays using allogeneic human PBMC and Laz509 cells as well
as xenogeneic porcine L23 cells as stimulators for human PBMC. Under all experimental con-
ditions, the presence of sera from LEA29Y transgenic animals resulted in clear-cut inhibition
of proliferation compared to sera fromWT controls (Fig 9B).
Discussion
So far, most studies on transplantation outcomes involving co-stimulation blockade by
CTLA4-Ig or LEA29Y have been performed by administering the immuno-modulating agents
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systemically. Despite LEA29Y having supported graft function as well as improved long-
term transplantation outcomes in kidney allotransplantation, the rate of acute graft failure
appeared to be higher with administration of LEA29Y than with the use of conventional
cyclosporine immuno-suppression [28–30]. Due to the systemic application of the co-stimu-
lation blockade, a detailed examination into the mechanism behind this observation has not
been feasible.
Providing local T cell regulation by transgene expression in the transplant is a unique
opportunity of xenotransplantation. The predominant approach has long been the transduc-
tion of the graft with viral vectors (reviewed in [31]), but this strategy suffers from overall poor
transduction efficiency, the limited penetration of the vectors into three-dimensional tissues,
the potential immunogenicity of the viral carriers as well as the only transient nature of trans-
gene expression. Stable transgene expression in xenotransplantation has primarily been
addressed in the context of complement-mediated rejection and coagulation incompatibilities
[3]. Numerous approaches for overcoming T cell-mediated rejection have also been
Fig 9. Biological evaluation of F1 animals. (A) CD80/CD86-positive porcine B cell line L23 and human B cell line laz509 were incubated with serial
dilutions of blood serum drawn from genetically modified F1 pigs and littermate controls. Labeled cells were analyzed for abundance of LEA29Y using a
goat anti-human IgG-FITC antibody. The results are expressed as the mean fluorescence intensity. (B) 105 human PBMCs were stimulated with
irradiated L23 cells, Laz509 cells or allogeneic PBMCs and 1:32 dilutions of serum from either CAG-LEA or wild-type animals. Proliferation was
determined after 5 d by [3H]-TdR incorporation (ccpm, counts/min). The results are expressed as the mean ± SD of triplicate cultures.
doi:10.1371/journal.pone.0155676.g009
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hypothesized, but their functional relevance to xenotransplantation has been evaluated only to
some extent [32, 33].
Local LEA29Y or CTLA4-Ig expression is the only T cell-regulating approach for which
functionality has been shown in stringent in vivomodels, either in pig-to-humanized-mouse
transplantation of islets [6], pig-to-rat transplantation of skin [8] or pig-to-primate transplan-
tation of corneas [34]. In all cases, grafts remained protected from T cell-mediated rejection
mechanisms for prolonged periods of time. For these studies, donor animals with cell-type-spe-
cific LEA29Y or CTLA4-Ig expression in the respective organs were utilized. Thus, interference
of transgene expression with the donor animal’s immune system was not given. However, to
provide multiple grafts from one donor or supply more complex, or even vascularized, grafts,
the ubiquitous expression of T cell modulators will be required. An earlier presentation of a
transgenic pig with generalized porcine CTLA4-Ig expression reported on the severely com-
promised immune system of these animals, which proved contradictory to their being raised to
maturity [10].
Here, we present a genetically modified pig line with ubiquitous expression of LEA29Y that
(i) produces a biologically active transgenic product at a considerable level in transplant-rele-
vant organs, (ii) presents with an immune system evidently affected by the transgene expres-
sion, but (iii), nevertheless, becomes sexually mature and can reproduce by assisted breeding
methods.
The demonstrated approach of IVF using epididymal sperm of the founder generation boar
has been successful in establishing a viable F1 generation of CAG-LEA pigs. These animals dis-
played an immunological phenotype comparable to the founder generation; however, the
clinical phenotype appeared less severe, as recurring infections in this generation could be
comparably easily treated and usually did not lead to premature euthanasia of the animals. A
number of CAG-LEA F1 pigs are now sexually mature and are presently being bred onto a
multi-transgenic background for xenotransplantation purposes. We hypothesize that the
reduced clinical phenotype in this F1 generation might be due to the attenuation of cloning
side effects that had been present for the founder generation and are known to affect the viabil-
ity and prosperity of pigs generated by SCNT [35]. However, importantly, the immunological
effects as well as the biological properties of the transgene, as demonstrated in binding studies
and proliferation assays, were fully reproduced in F1 animals, thereby confirming the inherit-
ability of the phenotype and offering the possibility for expanding this genetic modification by
breeding.
Additionally, the propagation of CAG-LEA pigs might be further optimized by improving
housing conditions. At present, pig models intended for biomedical research can be main-
tained under conventional agricultural conditions; however, in the future, these conditions will
likely no longer be accepted. Many institutions working on pig models are currently in the pro-
cess of establishing an infrastructure under defined pathogen-free (DPF) conditions, which
will aid the housing of such immune-compromised donor pigs further.
The immunological phenotype of CAG-LEA pigs illustrates the competence of the trans-
gene for modifying T cell activation processes in vivo. This might become an important facet in
future studies involving tissue or organs from this pig model in the context of xenotransplanta-
tion [36].
The induction of long-term graft survival in the recipient has long been a holy grail of trans-
plantation research. Most approaches in clinical studies have made use of adoptive transfer of
either Tregs [37, 38] or tolerogenic DCs [39, 40]. While the promising nature of such strategies
has been demonstrated in numerous rodent models, the mode of action in these therapeutic
approaches remains questionable. Ample evidence for the involvement of CTLA4 in the induc-
tion of peripheral tolerance has been published in past years, but the manner in which CTLA4
Viable Pigs with LEA29Y Expression
PLOS ONE | DOI:10.1371/journal.pone.0155676 May 13, 2016 17 / 22
contributes to this process has been intensely debated [41]. Recently, it has been postulated
that CLTA4 acts extracellularly toward other immune cells rather than by intracellular signal-
ing into Tregs alone [42, 43]. A downregulation of antigen-presenting cell (APC) function by
trans-endocytosing of B7.1/CD80 and B7.2/CD86 molecules from APC to Treg via CTLA4
binding has been postulated [44], but there is also strong evidence that CTLA4 acts on APCs
directly, as the co-incubation of tolerogenic DCs with CTLA4-Ig prior to adoptive transfer has
been shown sufficient to induce tolerance of the graft [45, 46]. A change in tryptophan metabo-
lism might be involved, as CTLA4 binding to CD80/CD86 activates IDO, a tryptophan-catabo-
lizing enzyme, in DCs, and blocking IDO by a specific inhibitor has diminished the protective
effect of CTLA4-Ig in an islet transplantation model [47, 48].
An alternative mode of action has been postulated very recently when it was shown that
CTLA4-Ig might also act by directly inducing a unique T cell phenotype, which in turn results
in an APC population that is less effective in promoting T cell activation and thus, inhibits sub-
sequent immune responses [49]. Interestingly, this study did not observe induction of IL-6 or
IDO and might represent a novel hypothesis on how CTLA4-Ig modulates T cell activation.
The above-mentioned unfavorable effect of systemic LEA29Y application has been ascribed
to a decrease in Treg populations, a blockade of endogenous CTLA4 signaling, and an up-regu-
lation of Th17 cells [30, 50]. These results also correlate with our detection of a strong down-
regulation of Tregs in CAG-LEA pigs, possibly mediated by the inhibition of CD28 binding to
its receptors, which is a prerequisite for inducing the FOXP3 Treg phenotype [51, 52].
Thus, improved transplantation success can be detected in conventional set-ups employing
a systemically administered LEA29Y immuno-suppression protocol; however, the exact func-
tion of the employed co-stimulation blockade remains difficult to determine. By restricting the
presence of CTLA4-Ig or LEA29Y to the graft, mechanistic evaluations can more easily be per-
formed while at the same time restricting the immuno-suppressive load on the recipient to a
minimum. Employing grafts from LEA29Y transgenic pigs in future experiments might con-
tribute to further clarification of the exact mode of action of LEA29Y by providing an opportu-
nity for detailed analysis in preclinical in vivo transplantation models.
Conclusion
Here, we report the establishment of a novel pig model with ubiquitous expression of LEA29Y.
These animals are viable, reproductive and produce a recombinant protein that may be capable
of modifying T cell-mediated rejection processes. This represents considerable progress toward
the control of cellular rejection in xenotransplantation and will provide a unique opportunity
for studying the LEA29Y mode of action in more detail in an in vivo large animal model.
Supporting Information
S1 Fig. Reproductive potential of CAG-LEA boars. (A) In vitro fertilization of oocytes was
performed using sperm from a re-cloned CAG-LEA boar. As controls, sperm from a different
transgenic (CD4TK) and aWT boar were used. (B) The developmental potential of in vitro fer-
tilized embryos was determined by their ability to develop to the blastocyst stage and the mean
cell number per blastocyst. (C) Day 7 blastocysts from IVM/IVF embryos with CAG-LEA fro-
zen sperm (left), and their blastocysts stained with aceto-orcein (right). Magnification: 200-fold.
(TIF)
S2 Fig. Propagation of CAG-LEA animals. (A) Transgene-specific genotyping was performed
on IVF-produced offspring of a re-cloned CAG-LEA boar. Control PCR was performed by
using primers for the ACTB gene. (B) Southern blotting of founder animals and F1 generation
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offspring was conducted using a radio-labelled (α32P-dCTP) probe specific for the neomycin
resistance cassette of the transgene as shown in Fig 3A. (C) PBMCs isolated at the beginning
(early) and end (late) of a three-month interval were analyzed by flow cytometry. Determina-
tion of CD4+ T cells subpopulations in transgenic IVF offspring revealed a reduced population
of effector memory (CD8α+CD27-) T cells (red).
(TIF)
S1 Table. Oligo nucleotides.
(PDF)
Author Contributions
Conceived and designed the experiments: AB NK EW AS RSWGMK. Performed the experi-
ments: AB NKWG TKWBMK BK NH EK KW AW ST. Analyzed the data: AB NK AS RS
KWWG. Contributed reagents/materials/analysis tools: HN. Wrote the paper: AB NK EW
WG KW EK AS RS MK.
References
1. Kim MK, Choi HJ, Kwon I, Pierson RN 3rd, Cooper DK, Soulillou JP, et al. The International Xenotrans-
plantation Association consensus statement on conditions for undertaking clinical trials of xenocorneal
transplantation. Xenotransplantation. 2014; 21(5):420–30. doi: 10.1111/xen.12129 PMID: 25176471
2. Matsumoto S, Tan P, Baker J, Durbin K, Tomiya M, Azuma K, et al. Clinical porcine islet xenotransplan-
tation under comprehensive regulation. Transplantation proceedings. 2014; 46(6):1992–5. doi: 10.
1016/j.transproceed.2014.06.008 PMID: 25131091.
3. Mohiuddin MM, Singh AK, Corcoran PC, Hoyt RF, Thomas ML 3rd, Lewis BG, et al. One-year hetero-
topic cardiac xenograft survival in a pig to baboon model. American journal of transplantation: official
journal of the American Society of Transplantation and the American Society of Transplant Surgeons.
2014; 14(2):488–9. doi: 10.1111/ajt.12562 PMID: 24330419; PubMed Central PMCID: PMC4184155.
4. Cooper DK, Ekser B, Ramsoondar J, Phelps C, Ayares D. The role of genetically engineered pigs in
xenotransplantation research. J Pathol. 2016; 238(2):288–99. doi: 10.1002/path.4635 PMID:
26365762; PubMed Central PMCID: PMCPMC4689670.
5. Weiss EH, Lilienfeld BG, Muller S, Muller E, Herbach N, Kessler B, et al. HLA-E/human beta2-microglo-
bulin transgenic pigs: protection against xenogeneic human anti-pig natural killer cell cytotoxicity.
Transplantation. 2009; 87(1):35–43. doi: 10.1097/TP.0b013e318191c784 PMID: 19136889.
6. Klymiuk N, van Buerck L, Bahr A, Offers M, Kessler B, Wuensch A, et al. Xenografted islet cell clusters
from INSLEA29Y transgenic pigs rescue diabetes and prevent immune rejection in humanized mice.
Diabetes. 2012; 61(6):1527–32. doi: 10.2337/db11-1325 PMID: 22522620; PubMed Central PMCID:
PMC3357306.
7. Martin C, Plat M, Nerriere-Daguin V, Coulon F, Uzbekova S, Venturi E, et al. Transgenic expression of
CTLA4-Ig by fetal pig neurons for xenotransplantation. Transgenic research. 2005; 14(4):373–84.
PMID: 16201404.
8. Wang Y, Yang HQ, Jiang W, Fan NN, Zhao BT, Ou-Yang Z, et al. Transgenic expression of human
cytoxic T-lymphocyte associated antigen4-immunoglobulin (hCTLA4Ig) by porcine skin for xenogeneic
skin grafting. Transgenic research. 2015; 24(2):199–211. doi: 10.1007/s11248-014-9833-9 PMID:
25236862.
9. Klymiuk N, Bocker W, Schonitzer V, Bahr A, Radic T, Frohlich T, et al. First inducible transgene expres-
sion in porcine large animal models. FASEB journal: official publication of the Federation of American
Societies for Experimental Biology. 2012; 26(3):1086–99. doi: 10.1096/fj.11-185041 PMID: 22138035.
10. Phelps CJ, Ball SF, Vaught TD, Vance AM, Mendicino M, Monahan JA, et al. Production and character-
ization of transgenic pigs expressing porcine CTLA4-Ig. Xenotransplantation. 2009; 16(6):477–85. doi:
10.1111/j.1399-3089.2009.00533.x PMID: 20042047.
11. Hall TA. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Win-
dows 95/98/NT. Nucl Acids Symp Ser 1999; 41:95–8.
12. Schwartz JC, Zhang X, Fedorov AA, Nathenson SG, Almo SC. Structural basis for co-stimulation by
the human CTLA-4/B7-2 complex. Nature. 2001; 410(6828):604–8. doi: 10.1038/35069112 PMID:
11279501.
Viable Pigs with LEA29Y Expression
PLOS ONE | DOI:10.1371/journal.pone.0155676 May 13, 2016 19 / 22
13. Plog S, Mundhenk L, Bothe MK, Klymiuk N, Gruber AD. Tissue and cellular expression patterns of por-
cine CFTR: similarities to and differences from human CFTR. The journal of histochemistry and cyto-
chemistry: official journal of the Histochemistry Society. 2010; 58(9):785–97. doi: 10.1369/jhc.2010.
955377 PMID: 20498480; PubMed Central PMCID: PMC2924795.
14. Matsuda T, Cepko CL. Electroporation and RNA interference in the rodent retina in vivo and in vitro.
Proceedings of the National Academy of Sciences of the United States of America. 2004; 101(1):16–
22. doi: 10.1073/pnas.2235688100 PMID: 14603031; PubMed Central PMCID: PMC314130.
15. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. Neonatal lethality and lymphope-
nia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell. 1991; 65(7):1153–63.
PMID: 2065352.
16. KuromeM, Kessler B, Wuensch A, Nagashima H, Wolf E. Nuclear transfer and transgenesis in the pig.
Methods in molecular biology. 2015; 1222:37–59. doi: 10.1007/978-1-4939-1594-1_4 PMID:
25287337.
17. Plege A, Borns K, BaarsW, Schwinzer R. Suppression of human T-cell activation and expansion of reg-
ulatory T cells by pig cells overexpressing PD-ligands. Transplantation. 2009; 87(7):975–82. doi: 10.
1097/TP.0b013e31819c85e8 PMID: 19352115.
18. Saalmuller A, Jonjic S, Buhring HJ, Reddehase MJ, Koszinowski UH. Monoclonal antibodies reactive
with swine lymphocytes. II. Detection of an antigen on resting T cells down-regulated after activation.
Journal of immunology. 1987; 138(6):1852–7. PMID: 2950172.
19. Meuer SC, Schlossman SF, Reinherz EL. Clonal analysis of human cytotoxic T lymphocytes: T4+ and
T8+ effector T cells recognize products of different major histocompatibility complex regions. Proceed-
ings of the National Academy of Sciences of the United States of America. 1982; 79(14):4395–9.
PMID: 6981813; PubMed Central PMCID: PMCPMC346678.
20. Kikuchi K, Nagai T, Kashiwazaki N, Ikeda H, Noguchi J, Shimada A, et al. Cryopreservation and ensu-
ing in vitro fertilization ability of boar spermatozoa from epididymides stored at 4 degrees C. Theriogen-
ology. 1998; 50(4):615–23. PMID: 10732152.
21. Yoshioka K, Suzuki C, Itoh S, Kikuchi K, Iwamura S, Rodriguez-Martinez H. Production of piglets
derived from in vitro-produced blastocysts fertilized and cultured in chemically defined media: effects of
theophylline, adenosine, and cysteine during in vitro fertilization. Biology of reproduction. 2003; 69
(6):2092–9. doi: 10.1095/biolreprod.103.020081 PMID: 12930720.
22. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobert E, et al. Rational development of
LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties.
American journal of transplantation: official journal of the American Society of Transplantation and the
American Society of Transplant Surgeons. 2005; 5(3):443–53. doi: 10.1111/j.1600-6143.2005.00749.x
PMID: 15707398.
23. Talker SC, Kaser T, Reutner K, Sedlak C, Mair KH, Koinig H, et al. Phenotypic maturation of porcine
NK- and T-cell subsets. Developmental and comparative immunology. 2013; 40(1):51–68. doi: 10.
1016/j.dci.2013.01.003 PMID: 23352625.
24. Saalmuller A, Werner T, Fachinger V. T-helper cells from naive to committed. Veterinary immunology
and immunopathology. 2002; 87(3–4):137–45. PMID: 12072228.
25. Reutner K, Leitner J, Mullebner A, Ladinig A, Essler SE, Duvigneau JC, et al. CD27 expression discrim-
inates porcine T helper cells with functionally distinct properties. Vet Res. 2013; 44:18. doi: 10.1186/
1297-9716-44-18 PMID: 23497134; PubMed Central PMCID: PMCPMC3610194.
26. Gil MA, Alminana C, Roca J, Vazquez JM, Martinez EA. Boar semen variability and its effects on IVF
efficiency. Theriogenology. 2008; 70(8):1260–8. doi: 10.1016/j.theriogenology.2008.06.004 PMID:
18676010.
27. Umeyama K, Honda K, Matsunari H, Nakano K, Hidaka T, Sekiguchi K, et al. Production of diabetic off-
spring using cryopreserved epididymal sperm by in vitro fertilization and intrafallopian insemination
techniques in transgenic pigs. J Reprod Dev. 2013; 59(6):599–603. PMID: 23979397; PubMed Central
PMCID: PMCPMC3934148.
28. Klintmalm GB, Feng S, Lake JR, Vargas HE, Wekerle T, Agnes S, et al. Belatacept-based immunosup-
pression in de novo liver transplant recipients: 1-year experience from a phase II randomized study.
American journal of transplantation: official journal of the American Society of Transplantation and the
American Society of Transplant Surgeons. 2014; 14(8):1817–27. doi: 10.1111/ajt.12810 PMID:
25041339; PubMed Central PMCID: PMC4140547.
29. Krummey SM, Cheeseman JA, Conger JA, Jang PS, Mehta AK, Kirk AD, et al. High CTLA-4 expression
on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. Amer-
ican journal of transplantation: official journal of the American Society of Transplantation and the Ameri-
can Society of Transplant Surgeons. 2014; 14(3):607–14. PMID: 24730049; PubMed Central PMCID:
PMC4124942.
Viable Pigs with LEA29Y Expression
PLOS ONE | DOI:10.1371/journal.pone.0155676 May 13, 2016 20 / 22
30. Riella LV, SayeghMH. T-cell co-stimulatory blockade in transplantation: two steps forward one step
back! Expert opinion on biological therapy. 2013; 13(11):1557–68. doi: 10.1517/14712598.2013.
845661 PMID: 24083381.
31. Hughes A, Jessup C, Drogemuller C, Mohanasundaram D, Milner C, Rojas D, et al. Gene therapy to
improve pancreatic islet transplantation for Type 1 diabetes mellitus. Current diabetes reviews. 2010; 6
(5):274–84. PMID: 20594165.
32. Ekser B, Ezzelarab M, Hara H, van der Windt DJ, WijkstromM, Bottino R, et al. Clinical xenotransplan-
tation: the next medical revolution? Lancet. 2012; 379(9816):672–83. doi: 10.1016/S0140-6736(11)
61091-X PMID: 22019026.
33. Nagaraju S, Bottino R, WijkstromM, Hara H, Trucco M, Cooper DK. Islet xenotransplantation from
genetically engineered pigs. Current opinion in organ transplantation. 2013; 18(6):695–702. doi: 10.
1097/MOT.0000000000000020 PMID: 24126804.
34. Vabres B, Le Bas-Bernardet S, Riochet D, Cherel Y, Minault D, Hervouet J, et al. hCTLA4-Ig transgene
expression in keratocytes modulates rejection of corneal xenografts in a pig to non-human primate
anterior lamellar keratoplasty model. Xenotransplantation. 2014; 21(5):431–43. doi: 10.1111/xen.
12107 PMID: 25040113.
35. KuromeM, Geistlinger L, Kessler B, Zakhartchenko V, Klymiuk N, Wuensch A, et al. Factors influencing
the efficiency of generating genetically engineered pigs by nuclear transfer: multi-factorial analysis of a
large data set. BMC biotechnology. 2013; 13:43. doi: 10.1186/1472-6750-13-43 PMID: 23688045;
PubMed Central PMCID: PMC3691671.
36. Yamada K, Sachs DH, DerSimonian H. Human anti-porcine xenogeneic T cell response. Evidence for
allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition.
Journal of immunology. 1995; 155(11):5249–56. PMID: 7594537.
37. Cobbold SP, Waldmann H. Regulatory cells and transplantation tolerance. Cold Spring Harbor per-
spectives in medicine. 2013; 3(6). doi: 10.1101/cshperspect.a015545 PMID: 23732858.
38. Edozie FC, Nova-Lamperti EA, Povoleri GA, Scotta C, John S, Lombardi G, et al. Regulatory T-cell
therapy in the induction of transplant tolerance: the issue of subpopulations. Transplantation. 2014; 98
(4):370–9. doi: 10.1097/TP.0000000000000243 PMID: 24933458.
39. Ezzelarab M, Thomson AW. Tolerogenic dendritic cells and their role in transplantation. Seminars in
immunology. 2011; 23(4):252–63. doi: 10.1016/j.smim.2011.06.007 PMID: 21741270; PubMed Central
PMCID: PMC3192911.
40. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nature
reviews Immunology. 2007; 7(8):610–21. doi: 10.1038/nri2132 PMID: 17627284.
41. Walker LS. Treg and CTLA-4: two intertwining pathways to immune tolerance. Journal of autoimmunity.
2013; 45:49–57. doi: 10.1016/j.jaut.2013.06.006 PMID: 23849743; PubMed Central PMCID:
PMC3989116.
42. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic
and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family.
Immunological reviews. 2011; 241(1):180–205. doi: 10.1111/j.1600-065X.2011.01011.x PMID:
21488898; PubMed Central PMCID: PMC3077803.
43. Walker LS, SansomDM. The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses.
Nature reviews Immunology. 2011; 11(12):852–63. doi: 10.1038/nri3108 PMID: 22116087.
44. Qureshi OS, Zheng Y, Nakamura K, Attridge K, Manzotti C, Schmidt EM, et al. Trans-endocytosis of
CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science. 2011; 332
(6029):600–3. doi: 10.1126/science.1202947 PMID: 21474713; PubMed Central PMCID:
PMC3198051.
45. Mayer E, Holzl M, Ahmadi S, Dillinger B, Pilat N, Fuchs D, et al. CTLA4-Ig immunosuppressive activity
at the level of dendritic cell/T cell crosstalk. International immunopharmacology. 2013; 15(3):638–45.
doi: 10.1016/j.intimp.2013.02.007 PMID: 23434857; PubMed Central PMCID: PMC3629566.
46. Tian M, Lv Y, Zhai C, Zhu H, Yu L, Wang B. Alternative immunomodulatory strategies for xenotrans-
plantation: CD80/CD86-CTLA4 pathway-modified immature dendritic cells promote xenograft survival.
PloS one. 2013; 8(7):e69640. doi: 10.1371/journal.pone.0069640 PMID: 23922766; PubMed Central
PMCID: PMC3726660.
47. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4-Ig regulates tryp-
tophan catabolism in vivo. Nature immunology. 2002; 3(11):1097–101. doi: 10.1038/ni846 PMID:
12368911.
48. Munn DH, SharmaMD, Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine
2,3-dioxygenase activity in dendritic cells. Journal of immunology. 2004; 172(7):4100–10. PMID:
15034022.
Viable Pigs with LEA29Y Expression
PLOS ONE | DOI:10.1371/journal.pone.0155676 May 13, 2016 21 / 22
49. Patakas A, Ji RR, Weir W, Connolly SE, Benson RA, Nadler SG, et al. Abatacept inhibits T cell priming
by inducing of a unique transcriptional profile that reduces their ability to activate antigen presenting
cells. Arthritis & rheumatology. 2015. doi: 10.1002/art.39470 PMID: 26473409.
50. Vondran FW, Timrott K, Kollrich S, Klempnauer J, Schwinzer R, Becker T. Decreased frequency of
peripheral CD4(+) CD161(+) Th(17) -precursor cells in kidney transplant recipients on long-term ther-
apy with Belatacept. Transplant international: official journal of the European Society for Organ Trans-
plantation. 2012; 25(4):455–63. doi: 10.1111/j.1432-2277.2012.01441.x PMID: 22348376.
51. Tai X, Cowan M, Feigenbaum L, Singer A. CD28 costimulation of developing thymocytes induces
Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nature immunol-
ogy. 2005; 6(2):152–62. doi: 10.1038/ni1160 PMID: 15640801.
52. Zhang R, Huynh A, Whitcher G, Chang J, Maltzman JS, Turka LA. An obligate cell-intrinsic function for
CD28 in Tregs. The Journal of clinical investigation. 2013; 123(2):580–93. doi: 10.1172/JCI65013
PMID: 23281398; PubMed Central PMCID: PMC3561819.
Viable Pigs with LEA29Y Expression
PLOS ONE | DOI:10.1371/journal.pone.0155676 May 13, 2016 22 / 22
